TY - JOUR
T1 - Solvent-based paclitaxel or nab-paclitaxel for heavily treated relapsed/refractory small cell lung cancer
AU - Sugiyama, Keiji
AU - Kogure, Yoshihito
AU - Torii, Atsushi
AU - Shiraishi, Kazuhiro
AU - Yamada, Arisa
AU - Ishida, Akane
AU - Shigematsu, Fumie
AU - Nozawa, Kazuki
AU - Niwa, Hideyuki
AU - Oka, Saori
AU - Nakahata, Masashi
AU - Kitagawa, Chiyoe
AU - Oki, Masahide
AU - Saka, Hideo
N1 - Publisher Copyright:
© 2019 the Author(s).
PY - 2019/3/1
Y1 - 2019/3/1
N2 - Treatment options for patients with relapsed/refractory small cell lung cancer (R/R SCLC) are limited, and the efficacy of salvage therapies for heavily treated patients should be assessed. Here, we evaluated the efficacy of paclitaxel (PTX) in R/R SCLC patients. A single-institute retrospective chart review was conducted. The primary endpoint was overall survival (OS), whereas the secondary endpoints were progression-free survival (PFS), overall response rate, disease control rate (DCR), and safety. Thirty-one patients (median age, 69 [range, 56-80] years) were analyzed. The median follow-up period was 122 (range, 28-1121) days. The median OS and PFS were 4.4 and 2.2 months, respectively. Adverse events of grade 3 or higher, other than hematological toxicity, were febrile neutropenia and neuropathy. Multivariate analyses identified the following independent predictors of poor OS: performance status and lactate dehydrogenase at the upper limit of normal. PTX monotherapy showed moderate efficacy with acceptable toxicity in heavily treated patients with R/R SCLC patients.
AB - Treatment options for patients with relapsed/refractory small cell lung cancer (R/R SCLC) are limited, and the efficacy of salvage therapies for heavily treated patients should be assessed. Here, we evaluated the efficacy of paclitaxel (PTX) in R/R SCLC patients. A single-institute retrospective chart review was conducted. The primary endpoint was overall survival (OS), whereas the secondary endpoints were progression-free survival (PFS), overall response rate, disease control rate (DCR), and safety. Thirty-one patients (median age, 69 [range, 56-80] years) were analyzed. The median follow-up period was 122 (range, 28-1121) days. The median OS and PFS were 4.4 and 2.2 months, respectively. Adverse events of grade 3 or higher, other than hematological toxicity, were febrile neutropenia and neuropathy. Multivariate analyses identified the following independent predictors of poor OS: performance status and lactate dehydrogenase at the upper limit of normal. PTX monotherapy showed moderate efficacy with acceptable toxicity in heavily treated patients with R/R SCLC patients.
UR - http://www.scopus.com/inward/record.url?scp=85062417452&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85062417452&partnerID=8YFLogxK
U2 - 10.1097/MD.0000000000014758
DO - 10.1097/MD.0000000000014758
M3 - Article
C2 - 30817634
AN - SCOPUS:85062417452
SN - 0025-7974
VL - 98
JO - Medicine (United States)
JF - Medicine (United States)
IS - 9
M1 - e14758
ER -
